Novel Biologicals for the Treatment of Allergic Diseases and Asthma

[1]  Norbert Meyer,et al.  Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. , 2016, The Journal of allergy and clinical immunology.

[2]  I. Agache,et al.  Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. , 2016, Allergology international : official journal of the Japanese Society of Allergology.

[3]  C. Akdis,et al.  Advances and highlights in mechanisms of allergic disease in 2015. , 2016, The Journal of allergy and clinical immunology.

[4]  T. Casale,et al.  Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. , 2016, The Journal of allergy and clinical immunology.

[5]  W. Busse,et al.  Biomarkers in asthmatic patients: Has their time come to direct treatment? , 2016, The Journal of allergy and clinical immunology.

[6]  S. Galli,et al.  Toward precision medicine and health: Opportunities and challenges in allergic diseases. , 2016, The Journal of allergy and clinical immunology.

[7]  H. Renz,et al.  Antisense molecules: A new class of drugs. , 2016, The Journal of allergy and clinical immunology.

[8]  A. Henning,et al.  A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. , 2016, The Journal of allergy and clinical immunology.

[9]  K. Nadeau,et al.  Molecular and cellular mechanisms of food allergy and food tolerance. , 2016, The Journal of allergy and clinical immunology.

[10]  A. Sheikh,et al.  Allergen immunotherapy for allergic asthma: protocol for a systematic review , 2016, Clinical and Translational Allergy.

[11]  H. Nakagawa,et al.  The first trial of CIM331, a humanized antihuman interleukin‐31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double‐blind, placebo‐controlled study , 2016, The British journal of dermatology.

[12]  A. Bush,et al.  Type 2 innate lymphoid cells in induced sputum from children with severe asthma. , 2016, The Journal of allergy and clinical immunology.

[13]  Steven G. Smith,et al.  Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. , 2015, The Journal of allergy and clinical immunology.

[14]  S. Szefler,et al.  New and future strategies to improve asthma control in children. , 2015, The Journal of allergy and clinical immunology.

[15]  D. Broide,et al.  Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis. , 2015, The Journal of allergy and clinical immunology.

[16]  P. O'Byrne,et al.  Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. , 2015, The Lancet. Respiratory medicine.

[17]  I. Agache,et al.  The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside , 2015, Current Allergy and Asthma Reports.

[18]  F. Spertini,et al.  EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders , 2015, Allergy.

[19]  Z. Modrušan,et al.  IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells. , 2015, The Journal of allergy and clinical immunology.

[20]  C. Akdis,et al.  T-cell regulation during viral and nonviral asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[21]  I. Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2015, The New England journal of medicine.

[22]  T. Casale,et al.  Role of biologics in intractable urticaria , 2015, Biologics : targets & therapy.

[23]  F. Annunziato,et al.  The 3 major types of innate and adaptive cell-mediated effector immunity. , 2015, The Journal of allergy and clinical immunology.

[24]  C. Akdis,et al.  IL-10-overexpressing B cells regulate innate and adaptive immune responses. , 2015, The Journal of allergy and clinical immunology.

[25]  S. Wenzel,et al.  Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. , 2015, The Journal of allergy and clinical immunology.

[26]  K. Nadeau,et al.  The future of biologics: applications for food allergy. , 2015, The Journal of allergy and clinical immunology.

[27]  G. Sussman,et al.  Chronic idiopathic urticaria: treatment with omalizumab. , 2014, Skin therapy letter.

[28]  A. Cianferoni,et al.  The importance of TSLP in allergic disease and its role as a potential therapeutic target , 2014, Expert review of clinical immunology.

[29]  M. Akdiş.  New treatments for allergen immunotherapy , 2014, The World Allergy Organization journal.

[30]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[31]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[32]  R. Maciuca,et al.  Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production , 2014, Science Translational Medicine.

[33]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[34]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[35]  E. Ntzani,et al.  Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. , 2014, The journal of allergy and clinical immunology. In practice.

[36]  F. A. Roldán,et al.  Ustekinumab en el tratamiento de la dermatitis atópica severa. Nuestra experiencia en 4 pacientes. Informe preliminar , 2014 .

[37]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.

[38]  C. Akdis,et al.  MicroRNAs in Allergy and Asthma , 2014, Current Allergy and Asthma Reports.

[39]  J. Hébert,et al.  Real-life experiences with omalizumab for the treatment of chronic urticaria. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[40]  T. Illig,et al.  Increased efficacy of omalizumab in atopic dermatitis patients with wild‐type filaggrin status and higher serum levels of phosphatidylcholines , 2014, Allergy.

[41]  E. Blood,et al.  Food , drug , insect sting allergy , and anaphylaxis A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients , 2013 .

[42]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[43]  J. Bird,et al.  Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.

[44]  S. Wenzel,et al.  Dupilumab in persistent asthma. , 2013, The New England journal of medicine.

[45]  R. Leigh,et al.  A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma , 2013, Respiratory Research.

[46]  Simon Francis Thomsen,et al.  TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients , 2013, Journal of allergy.

[47]  S. Mosesova,et al.  Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. , 2013, The Journal of allergy and clinical immunology.

[48]  F. Messeguer,et al.  Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab , 2013, Annals of dermatology.

[49]  K. Bergmann,et al.  Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy , 2013, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[50]  S. Durham,et al.  Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. , 2013, The Journal of allergy and clinical immunology.

[51]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[52]  K. Nadeau,et al.  Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial , 2013, International Archives of Allergy and Immunology.

[53]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[54]  I. Agache.  From phenotypes to endotypes to asthma treatment , 2013, Current opinion in allergy and clinical immunology.

[55]  D. Leung,et al.  New era of biologic therapeutics in atopic dermatitis , 2013, Expert opinion on biological therapy.

[56]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[57]  H. Magnussen,et al.  The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers , 2013, European Respiratory Journal.

[58]  T. Casale,et al.  Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. , 2012, The Journal of allergy and clinical immunology.

[59]  J. Virchow,et al.  Untangling asthma phenotypes and endotypes , 2012, Allergy.

[60]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[61]  C. Akdis.  Therapies for allergic inflammation: refining strategies to induce tolerance , 2012, Nature Medicine.

[62]  E. Kocaturk,et al.  Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey , 2012, The Journal of dermatology.

[63]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[64]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy , 2012, Clinical and Translational Allergy.

[65]  J. Moreno,et al.  Treatment of severe refractory adult atopic dermatitis with ustekinumab , 2012, International journal of dermatology.

[66]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[67]  R. Hoffmann,et al.  Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells , 2011, European Respiratory Journal.

[68]  K. Schäkel,et al.  Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. , 2011, The Journal of allergy and clinical immunology.

[69]  C. Akdis,et al.  IL‐33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma , 2011, European journal of immunology.

[70]  K. Nadeau,et al.  Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. , 2011, The Journal of allergy and clinical immunology.

[71]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[72]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[73]  W. White,et al.  Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma , 2011, BMC pulmonary medicine.

[74]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[75]  M. Kopp.  Omalizumab: Anti-IgE Therapy in Allergy , 2011, Current allergy and asthma reports.

[76]  I. Pavord,et al.  Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.

[77]  J. Monroe,et al.  B‐cell targeted therapies in human autoimmune diseases: an updated perspective , 2010, Immunological reviews.

[78]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[79]  W. Paul,et al.  How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.

[80]  A. Gounni,et al.  Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. , 2010, The Journal of allergy and clinical immunology.

[81]  S. Amiel,et al.  Rituximab and omalizumab in severe, refractory insulin allergy. , 2009, The New England journal of medicine.

[82]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[83]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[84]  K. Okubo,et al.  Re-Treatment with Omalizumab at One Year Interval for Japanese Cedar Pollen-Induced Seasonal Allergic Rhinitis Is Effective and Well Tolerated , 2009, International Archives of Allergy and Immunology.

[85]  P. O'Byrne,et al.  Sputum eosinophils and the response of exercise-induced bronchoconstriction to corticosteroid in asthma. , 2008, Chest.

[86]  P. Hawkins,et al.  Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Follow-Up , 2008, Journal of cutaneous medicine and surgery.

[87]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[88]  Vicki Seyfert-Margolis,et al.  Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. , 2007, The Journal of allergy and clinical immunology.

[89]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[90]  J. Douwes,et al.  Innate immune activation in neutrophilic asthma and bronchiectasis , 2007, Thorax.

[91]  J. Ring,et al.  No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients , 2006, International Archives of Allergy and Immunology.

[92]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[93]  S. Friedlander,et al.  Etanercept is minimally effective in 2 children with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[94]  J. Ring,et al.  Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis , 2005, Allergy.

[95]  G. Schuler,et al.  Infliximab in the treatment of moderate to severe atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[96]  A. Togias,et al.  Omalizumab-induced reductions in mast cell FcεRI expression and function , 2004 .

[97]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[98]  I. Pavord,et al.  TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. , 2002, The Journal of allergy and clinical immunology.

[99]  I. Pavord,et al.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids , 2002, Thorax.

[100]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[101]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[102]  S. L. Smith.  Ten years of Orthoclone OKT3 (muromonab-CD3): a review. , 1996, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization.

[103]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[104]  Paulina,et al.  Interleukins , from 1 to 38 , interferons , transforming growth factor-and tumor necrosis factor-alpha : receptors , functions and roles in diseases , 2017 .

[105]  M. C. Fernández-Antón Martínez,et al.  Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. , 2014, Actas dermo-sifiliograficas.

[106]  Y. Gon,et al.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma , 2013 .

[107]  S. Willsie.  Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-Controlled Study , 2012 .

[108]  S. Willsie.  Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia , 2010 .

[109]  K. Okubo,et al.  Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[110]  A. Togias,et al.  Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. , 2004, The Journal of allergy and clinical immunology.